Actuate Therapeutics Stock Price, News & Analysis

Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company in the biotechnology and healthcare sector. According to its SEC filings and public disclosures, Actuate focuses on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3), with a particular emphasis on the beta isoform, GSK-3β.

The company’s lead investigational drug is elraglusib (formerly 9-ING-41), an ATP-competitive small-molecule inhibitor of GSK-3β. Actuate’s registration statement describes elraglusib as being designed to enter cancer cells and block GSK-3β, a master regulator of complex biological signaling cascades, including oncogene-mediated pathways that support tumor cell survival, growth, migration, and invasion. The company states that blocking GSK-3β signaling can lead to cancer cell death and regulation of anti-tumor immunity.

Clinical-stage oncology focus

Actuate characterizes itself as a clinical-stage biopharmaceutical company with programs in multiple solid tumors and hematologic malignancies that are historically difficult to treat. Across its public communications, the company repeatedly highlights metastatic pancreatic cancer, recurrent and metastatic salivary gland carcinoma, and refractory pediatric cancers such as Ewing sarcoma and neuroblastoma as key areas of clinical investigation for elraglusib.

In metastatic pancreatic ductal adenocarcinoma (mPDAC), Actuate reports results from the randomized, controlled Phase 2 Actuate-1801 Part 3B trial (NCT03678883). In this first-line mPDAC study, patients received either elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) or GnP alone. The company states that the trial met its primary endpoint, showing a statistically significant improvement in median overall survival for the elraglusib/GnP arm compared with GnP alone, with a reported reduction in the risk of death and higher 12‑ and 24‑month survival estimates in the combination arm. Actuate also notes that safety and tolerability for elraglusib in this setting were consistent with previously reported data, with no new safety signals identified.

Actuate further discloses that tumor biopsies from elraglusib-treated mPDAC patients showed increased CD8‑positive and granzyme B‑positive T cells, increased natural killer (NK) cells, and decreased myeloid-derived suppressor cells. The company presents these findings as evidence supporting elraglusib’s proposed immune-modulating mechanism of action in pancreatic cancer, in addition to its direct effects on tumor cell signaling and DNA damage response pathways.

Mechanism of action and scientific rationale

Across its press releases and SEC filings, Actuate describes elraglusib as a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer drugs. The company states that elraglusib can inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF‑κB) and DNA Damage Response (DDR) pathways. By influencing these pathways, elraglusib is intended to reduce tumor cell survival and enhance the effectiveness of chemotherapy.

Actuate also reports that elraglusib may mediate anti-tumor immunity through regulation of multiple immune checkpoints and immune cell function. In its communications, the company links GSK-3β inhibition to increased activity of T cells and NK cells and to changes in the tumor microenvironment that may support more effective immune responses against cancer.

Key clinical programs and indications

Actuate’s disclosures outline several clinical programs built around elraglusib:

• Metastatic pancreatic cancer (mPDAC): The Actuate-1801 Part 3B Phase 2 trial evaluates elraglusib plus gemcitabine/nab-paclitaxel versus GnP alone in first-line mPDAC. The company reports that the study met its primary endpoint with a statistically significant overall survival benefit for the combination arm. Actuate has amended its investigational new drug (IND) application with updated data from this study and indicates that these data are intended to support planned regulatory submissions to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA.
• Advanced pancreatic adenocarcinoma combinations: Actuate describes an investigator-initiated Phase 1b trial (RiLEY, NCT06896188) at UPMC Hillman Cancer Center in collaboration with Incyte Corporation. This study evaluates elraglusib in combination with Incyte’s PD‑1 inhibitor retifanlimab and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma. The trial’s primary objective is to determine the recommended Phase 2 dose for the combination, with secondary objectives including overall response rate, disease control rate, progression-free survival, overall survival, and safety.
• Additional pancreatic cancer study: Actuate notes a separate investigator-initiated Phase 2 trial (NCT05077800) studying elraglusib in combination with FOLFIRINOX and losartan in treatment‑naïve mPDAC patients, with early data indicating deep and durable responses in patients with extensive liver metastases.
• Recurrent, metastatic salivary gland carcinoma: The company highlights a Phase II trial (NCT05010629) of elraglusib (9‑ING‑41) plus platinum chemotherapy (carboplatin or cisplatin), with or without sequential pembrolizumab priming, in advanced metastatic salivary gland cancers, including adenoid cystic carcinoma (ACC) and non‑ACC subtypes. Actuate reports median progression-free survival and overall survival figures for the study population and emphasizes that nuclear GSK‑3β expression was higher in responders than non‑responders, suggesting that this biomarker may help identify patients more likely to benefit from elraglusib-based regimens.
• Refractory pediatric cancers and Ewing sarcoma: Through the Actuate‑1902 Phase 1/2 trial (NCT04239092), Actuate has evaluated elraglusib as monotherapy and in combination with chemotherapy regimens (including irinotecan-based combinations and cyclophosphamide/topotecan) in pediatric patients with relapsed or refractory malignancies. The company reports clinical responses and disease control in multiple pediatric cancer types, including Ewing sarcoma, neuroblastoma, central nervous system tumors, non‑Ewing sarcomas, and desmoplastic small round cell tumor (DSRCT). Actuate notes that complete responses and durable stable disease were observed in heavily pretreated Ewing sarcoma patients and that these findings support advancing elraglusib into a planned Phase 2 program in relapsed/refractory Ewing sarcoma across children, adolescents, and adults.

Regulatory and capital markets activity

Actuate’s SEC filings show that the company is listed on The Nasdaq Stock Market LLC under the symbol ACTU and is classified as an emerging growth company and smaller reporting company. The company has used both private placements and public offerings of common stock to fund its operations.

In June 2025, Actuate entered into a securities purchase agreement for a private placement of common stock and warrants with institutional and accredited investors, with the stated intention to use net proceeds for working capital and general corporate purposes. The associated registration rights agreement provides for the registration of the shares and warrant shares for resale. In September 2025, Actuate completed an underwritten public offering of common stock under an effective shelf registration statement on Form S‑3, again indicating that proceeds would be used for working capital and general corporate purposes.

The company has also filed a registration statement on Form S‑1 relating to the resale of shares and warrant shares held by certain selling stockholders. Actuate’s filings emphasize that it relies on external capital to finance its development activities and that it faces risks related to its ability to continue as a going concern without additional funding.

Information channels and investor communications

In a Form 8‑K, Actuate states that it disseminates material information through multiple channels, including its website, press releases, SEC filings, and social media accounts on platforms such as X (formerly Twitter), LinkedIn, and Facebook. The company encourages investors to review these sources for updates on its technology, clinical and corporate developments, and other matters. Actuate’s disclosures indicate that it uses these channels, together with traditional SEC reporting, to provide broad access to information about its business and clinical programs.

Business model and risk profile

Actuate’s registration statement and forward-looking statements in its press releases describe a business model centered on researching, developing, and seeking regulatory approval for oncology therapeutics based on GSK‑3 inhibition. The company’s revenue prospects are tied to the clinical and regulatory progress of elraglusib and any future product candidates it may develop or in‑license. Actuate notes that it relies on third parties to conduct non-clinical studies and clinical trials and on third-party licensors to preserve and protect certain intellectual property rights.

The company repeatedly cautions that clinical and preclinical drug development is lengthy, expensive, and uncertain, and that results from early-stage trials and subgroup analyses may not predict future outcomes. Actuate also highlights risks related to potential side effects or safety issues with elraglusib, competition from other biotechnology and pharmaceutical companies, and the need for additional capital to fund development activities and operations.

Position within the biotechnology sector

Within the biotechnology and healthcare sector, Actuate presents itself as focused on targeted oncology and immuno-oncology approaches built around GSK‑3β inhibition. Its clinical programs span adult and pediatric cancers, including pancreatic cancer, salivary gland carcinoma, and Ewing sarcoma, where unmet medical needs and limited treatment options are frequently cited in its communications. By combining elraglusib with established chemotherapies and immunotherapies in multiple investigator-initiated and company-sponsored trials, Actuate aims to explore how modulation of tumor signaling and anti-tumor immunity may translate into improved clinical outcomes in these challenging indications.